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ABSTRACT
Background: In the absence of dose-response data, Dietary Refer-
enceValues for vitaminD in nonpregnant adults are extended to preg-
nancy.
Objective: The aim was to estimate vitamin D intake needed to
maintain maternal 25-hydroxyvitamin D [25(OH)D] in late gestation
at a concentration sufficient to prevent newborn 25(OH)D <25–30
nmol/L, a threshold indicative of increased risk of nutritional rickets.
Design: We conducted a 3-arm, dose-response, double-blind, ran-
domized placebo-controlled trial in Cork, Ireland (51.9oN). A total
of 144 white-skinned pregnant women were assigned to receive 0,
10 (400 IU), or 20 (800 IU) µg vitamin D3/d from ≤18 wk of ges-
tation. Vitamin D metabolites at 14, 24, and 36 wk of gestation and
in cord sera, including 25(OH)D3, 3-epi-25(OH)D3, 24,25(OH)2D3,
and 25(OH)D2 were quantified by liquid chromatography–tandem
mass spectrometry. A curvilinear regression model predicted the
total vitamin D intake (from diet and antenatal supplements plus
treatment dose) that maintained maternal 25(OH)D in late ges-
tation at a concentration sufficient to maintain cord 25(OH)D at
≥25–30 nmol/L.
Results: Mean ± SD baseline 25(OH)D was 54.9 ± 10.7 nmol/L.
Total vitamin D intakes at the study endpoint (36 wk of gestation)
were 12.1 ± 8.0, 21.9 ± 5.3, and 33.7 ± 5.1 µg/d in the placebo
and 10-µg and 20-µg vitamin D3 groups, respectively; and 25(OH)D
was 24.3 ± 5.8 and 29.2 ± 5.6 nmol/L higher in the 10- and 20-µg
groups, respectively, compared with placebo (P < 0.001). For ma-
ternal 25(OH)D concentrations ≥50 nmol/L, 95% of cord sera were
≥30 nmol/L and 99% were >25 nmol/L. The estimated vitamin D
intake required to maintain serum 25(OH)D at≥50 nmol/L in 97.5%
of women was 28.9 µg/d.
Conclusions: Thirty micrograms of vitamin D per day safely main-
tained serum 25(OH)D concentrations at ≥50 nmol/L in almost all
white-skinned women during pregnancy at a northern latitude, which
kept 25(OH)D at >25 nmol/L in 99% and ≥30 nmol/L in 95% of
umbilical cord sera. This trial was registered at www.clinicaltrials.
gov as NCT02506439. Am J Clin Nutr 2018;108:77–91.
Keywords: 25-hydroxyvitamin D, dietary requirements, dose-
response, ODIN, neonatal, pregnancy, randomized controlled trial,
vitamin D, vitamin D requirements
INTRODUCTION
There is currently insufficient evidence from randomized con-
trolled trials (RCTs) to determine whether 25-hydroxyvitamin D
[25(OH)D] targets specific for perinatal outcomes are required
(1–4). Thus, Dietary Reference Values for vitamin D, which are
the recommended intakes to meet 25(OH)D targets of between 25
and 50 nmol/L for bone health outcomes, have been extended to
pregnancy and lactation (summarized in Table 1) (5). Although
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TABLE 1
Summary of the current dietary recommendations for vitamin D in pregnant women1
25(OH)D threshold, nmol/L Vitamin D, µg/d
Agency, year (ref) Region Deficiency Population average Individual target EAR RI
IOM (2011) (1) United States/Canada <30 40 ≥50 10 15
NORDEN (2012) (2) Nordic <30 — ≥50 7.5 10
SACN (2016) (3) United Kingdom <25 — ≥25 — 10
EFSA (2016) (4) EU — — ≥50 — 15 (AI)
1Table modified and reproduced from reference 5. AI, Adequate Intake; EAR, Estimated Average Requirement; EFSA, European
Food Safety Authority; IOM, Institute of Medicine; NORDEN, Nordic Council of Ministers; ref, reference; RI, Recommended (individ-
ual) Intake; SACN, Scientific Advisory Committee on Nutrition; 25(OH)D, 25-hydroxyvitamin D.
setting Dietary Reference Values is an iterative process, reliant on
the evidence basis at that time, the current recommendations for
vitamin D during pregnancy suffer from a lack of evidence across
a number of criteria. Not only are they not specific for perinatal
health outcomes, they do not consider fetal and neonatal require-
ments specifically and rely on an assumption that pregnancy does
not increase the metabolic demand for vitamin D.
Endemic vitamin D deficiency has been reported among preg-
nant women and newborns worldwide, with wide variations be-
tween and within regions. In the systematic review by Saraf
et al. (6), the global prevalence of 25(OH)D concentrations
<50 nmol/L was 54% among pregnant women and 75% among
newborns, whereas 18% of pregnant women and 29% of new-
borns had concentrations <25 nmol/L, a threshold identified as
indicative of an increased risk of nutritional rickets (1–4). Ac-
knowledging that neonatal requirements for 25(OH)D are un-
known and the application of adult references to newborns may
be questionable (7), it seems prudent nonetheless to ensure main-
tenance of newborn circulating 25(OH)D above a minimum of
25–30 nmol/L, consistent with the prevention of nutritional rick-
ets (8, 9). Because cord 25(OH)D concentrations are usually
∼60–80% of maternal values at delivery (10, 11), maintenance
of maternal 25(OH)D >25–30 nmol/L will not ensure newborn
protection at the same threshold. In the absence of sufficient trial-
based data to set maternal requirements for 25(OH)D on the
basis of perinatal outcomes, we propose in the interim that di-
etary recommendations for vitamin D during pregnancy should
be established with the aim of maintaining maternal 25(OH)D in
late gestation at sufficient concentrations to ensure that newborn
25(OH)D concentrations are ≥25–30 nmol/L. Researchers in
New Zealand and Canada have proposed that maternal 25(OH)D
should be maintained at 50 nmol/L (12, 13). To our knowledge,
this is the first placebo-controlled, dose-response, randomized
trial that was designed specifically to estimate the maternal vi-
tamin D intake needed to maintain serum 25(OH)D in late gesta-
tion at a concentration sufficient to keep umbilical cord 25(OH)D
≥25–30 nmol/L, a threshold indicative of increased risk of nutri-
tional rickets.
METHODS
This trial was conducted as part of the European Commission–
funded collaborative project ODIN (Food-based solutions
for optimal vitamin D nutrition and health throughout life;
www.odin-vitd.eu). This study was a 3-arm, parallel,
dose-response, double-blind, randomized trial of vitamin D3
(cholecalciferol) compared with placebo.
Participants
A total of 144 healthy, pregnant women were recruited
to the trial. Recruitment began in November 2014 and con-
tinued until April 2016. The primary center for recruitment
was the Cork University Maternity Hospital, Cork, Ireland,
where women attending early pregnancy and ultrasound clin-
ics were approached by a member of the study team and
informed about the trial. Social media and advertisements in
local General Practitioners surgeries and pharmacies provided
another avenue for recruitment. Women were considered eligi-
ble for participation if they were white-skinned adults ≥18 y
of age, with a gravidae of ≤18 wk of gestation, in good gen-
eral health, and not identified as having a high-risk pregnancy.
Exclusion criteria were as follows: current smoker, vegan, di-
agnosed hypertension before commencement of the study, diag-
nosed medical disorder including type 1 or 2 diabetes, chronic
kidney disease or gastrointestinal disease, consumption of med-
ications known to interfere with vitamin D metabolism (e.g.,
corticosteroids), and consumption of supplemental vitamin D
[>10 µg/d (>400 IU)] or calcium (>650 mg/d) before ran-
domization. Women were permitted to continue with self-
administration of antenatal supplements containing ≤10 µg vita-
min D/d but were excluded from the study if personal supplement
use exceeded this dose.
Sample size
The power calculation for this studywas based on similar dose-
response studies of vitamin D nutritional requirements designed
by our research group, whereby 31 participants/arm are adequate
to detect a 10-nmol/L difference in 25(OH)D concentrations and
provide 90% power to show a dose-response relation with a slope
of 1.5 and α = 0.05 (14–17). Because this was a pregnancy study,
with 3 assessment points at baseline and the second and third
trimesters, it was implemented throughout the year, unlike our
previous trials in other population subgroups, which were con-
ducted during winter. Therefore, we increased the sample size
to 48/arm (144 in total) to enable a season-specific analysis and
to account for a potentially higher drop-out rate in late gestation
than we would usually see (typically, ≤15%).
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Ethics
Ethical approval was obtained from the Clinical Re-
search Ethics Committee of the Cork Teaching Hospitals
[ECM4(o)04/02/14] and written informed consent was provided
by all women before commencing the trial. The study protocol
followed the guidelines laid down in the Declaration of Helsinki,
and the trial was registered at the US NIH Clinical Trials Registry
(www.clinicaltrials.gov; ID: NCT02506439).
Randomization
Given that this was a single-sex sample, within the reproduc-
tive age range, women were randomly assigned to receive 10 µg
(400 IU) or 20 µg (800 IU) vitamin D3/d or a matching placebo
in a 1:1:1 ratio (Figure 1). A senior scientist, who was not in-
volved in the implementation or analysis of the study, randomly
assigned group codes to a computer-generated list of random
numbers, which were assigned to consecutive participant iden-
tification numbers. Participants were allocated an identification
number in order of attendance of the baseline visit. The treatment
allocation was blinded to participants and investigators through-
out the study period.
Intervention
Placebo and Minisun vitamin D3 tablets were provided
by OY Verman Ab. All tablets (placebo and 10- and 20-µg
vitamin D3) were identical in appearance and taste and free from
sugar, lactose, yeast, gluten, and gelatin. Tablets were packaged
and coded into identical, white, plastic containers in a food sen-
sory facility at our center, ensuring concealment of the treatment
to the study team and participants. Independent analysis of the
vitamin D content of the study tablets was conducted by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) at the
National Food Institute at the Technical University of Denmark.
All of the analyses were based on a sample of 5 tablets and were
performed in triplicate. The content of the placebo and the 10- and
20-µg labeled tablets corresponded to a value of<0.02, 10.9, and
22.4 µg vitamin D3, respectively. The dose range of vitamin
D was chosen on the basis of the distribution of intakes and
25(OH)D concentrations observed in our previous dose-response
vitamin D trials (14, 15). We estimated that the mean intake in
the 20 µg group would be ∼25 µg/d (1000 IU), accounting for
the average contribution of the diet to vitamin D intakes in Ire-
land (18). In the current study, given that women were allowed
to continue with their own supplements as long as these did not
provide >10 µg/d, we estimated that the range of total intakes in
the sample from the base diet, fortified foods, personal antenatal
supplements, and assigned trial supplements would lie between
1 and ∼50 µg/d. We aimed to include a supplemental dose that
would ensure a total vitamin D intake that would not exceed the
accepted Tolerable Upper Intake Level of 100 µg/d (1). All of the
participants received a container of 90 tablets at both the base-
line and midpoint visits, corresponding to 1 tablet/d for up to 14
wk. Compliance was monitored by a tablet count at each visit,
and noncompliance was defined a priori as tablet consumption
<80%.
Data collection
All of the study visits took place at the Human Nutrition Stud-
ies Unit at the Cork Center for Vitamin D and Nutrition Re-
search, University College Cork, Cork, Ireland. The RCT was
conducted in compliance with Good Clinical Practice. Partici-
pants were seen 3 times throughout their pregnancy: at baseline
(14 wk of gestation; range: 8–18 wk), midgestation (24 wk of
gestation; range: 20–26 wk), and late gestation (36 wk of gesta-
tion; range: 34–38 wk). Gestational age was established by date
of last menstrual period and confirmed by fetal ultrasound at the
participants’ first ultrasound visit. At baseline, interviewer-led
assessments collected information on general health, lifestyle,
and sociodemographic characteristics. Habitual calcium and vi-
tamin D intakes were estimated by using a validated interviewer-
administered quantitative food-frequency questionnaire for vita-
min D and calcium (19) at baseline, and antenatal supplement
use was re-assessed at the second and third study visit to account
for any changes in supplemental vitamin D or calcium intake.
Anthropometric measurements (height and weight) were taken at
baseline with the use of standard scales (Leicester height mea-
sure; CMS Weighing Equipment Ltd.; digital weighing scales;
Seca Ltd.), and body weight measurements were repeated at the
second and third visits. Weight was measured in kilograms, with-
out shoes or heavy clothing, to the nearest 2 decimal places. A ve-
nous nonfasting blood sample (30mL)was collected at each visit,
because it would be inappropriate to request a pregnant woman to
fast. Blood samples were taken by a research nurse and processed
to serum within 3 h. A venous umbilical cord blood sample was
collected at delivery, refrigerated immediately, and processed to
serum at University College Cork. All of the blood samples were
stored at –80˚C until further analysis.
Laboratory analysis
Serum 25(OH)D concentrations
Circulating serum 25-hydroxyvitamin D3 [25(OH)D3],
3-epimer of 25-hydroxyvitamin D3 [3-epi-25(OH)D3], 24,25-
dihydroxyvitamin D3 [24,25(OH)2D3], and 25-hydroxyvitamin
D2 [25(OH)D2] were analyzed at the Cork Center for Vitamin
D and Nutrition Research using a CDC-certified LC-MS/MS
method, which has been described in detail elsewhere (20).
Briefly, the instrument used was a Waters Acquity UPLC system
coupled to an Acquity Triple Quadrupole (TQD) mass spectrom-
eter detector (Waters, Santry, Dublin 9, Ireland). Concentrations
of 25(OH)D3 and 25(OH)D2 were quantified separately and
summed to generate total 25(OH)D. Chromatographic separation
and quantification of 3-epi-25(OH)D3 were also achieved. Four
levels of serum-based National Institute of Standards and Tech-
nology (NIST)–certified quality-assurance material (SRM 972)
were used for method validation, whereas quality-control materi-
als assayed in parallel to all sampleswere purchased fromChrom-
systems. NIST calibrators (SRM 2972) were used throughout the
analysis. The intra-assay CVs for 25(OH)D3, 3-epi-25(OH)D3,
24,25(OH)2D3, and 25(OH)D2 were 2.5%, 12.7%, 9.3%, and
8.5% and the interassay CVs were 6.4%, 10.6%, 7.2%, and 3.5%,
respectively. The limits of detection (LoDs) for 25(OH)D3, 3-
epi-25(OH)D3, 24,25(OH)2D3, and 25(OH)D2 were 0.31, 0.12,
0.65, and 0.17 nmol/L and the limits of quantification were 2.52,
1.35, 1.09, and 2.19 nmol/L, respectively. Mean biases were
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FIGURE 1 CONSORT flow diagram of participant enrollment, random assignment, and biochemical analysis throughout the study by treatment group,
where n is based on the total number of samples available for each visit. Any participant who did not provide a blood sample at baseline was included in
the descriptive and biochemical analysis at later time points but excluded from the dose-response analysis, whereas women missing a midpoint sample only
were included in both the dose-response analysis and the analysis at endpoint, if a blood sample was collected at this time point. The numbers of women who
provided both a baseline and ≥1 follow-up sample (midpoint or endpoint) were 43, 42, and 43 for the placebo and 10- and 20-µg groups, respectively, which
left a final number of 128 for the dose-response analysis. CONSORT, Consolidated Standards of Reporting Trials; inclu., including.
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−1.5%, −4.9%, 12.0%, and −1.7%, respectively. Our method
does not measure the C-3 epimer of 25(OH)D2, but given the
low mean ± SD concentrations of 25(OH)D2 found in sera
from pregnant women (3.7 ± 2.7 nmol/L) (20) and umbilical
cords (2.2 ± 1.9 nmol/L) (9), extremely low concentrations of
3-epi-25(OH)D2 would be expected.
The quality and accuracy of the vitamin D metabolite analysis
in our laboratory are monitored on an ongoing basis by partic-
ipation in the Vitamin D External Quality Assessment Scheme
(DEQAS; Charing Cross Hospital, London, United Kingdom).
We have been certified by the CDC’s Vitamin D Standardiza-
tion Certification Program, which has reported accuracy and bias
for total 25(OH)D, 25(OH)D3, 3-epi-25(OH)D3, and 25(OH)D2
since 2013. For transparency, and to promote international com-
parison, we have reported data across a range of currently applied
international 25(OH)D thresholds (1–4, 21).
Serum calcium concentrations
As a safety measure, serum calcium is preferable to urinary
calcium in studies involving pregnant women because physio-
logic hypercalciuria can occur as a result of normal pregnancy
(1). Serum calcium and albumin were quantified at our labo-
ratory by colorimetric and immunoturbidimetric assays, respec-
tively, with the use of the Randox Monaco Automated Clinical
Chemistry Analyser (Randox Laboratories Ltd., Co.). Serum cal-
cium was corrected for albumin as follows: corrected calcium
(mmol/L) = measured total calcium (mmol/L) + 0.02 × [40 −
serum albumin (g/L)], where 40 represents the average albumin
concentration in grams per liter (22). Batch analysis allowed for
continuous sampling throughout the trial to ensure that all partic-
ipants remained below the predefined safety threshold (hypercal-
cemia defined as serum calcium ≥2.63 mmol/L) (1). A normal
reference range of 2.02–2.60 mmol/L is in agreement with that
provided by the manufacturer of the equipment used in this lab-
oratory (Randox Monaco, Randox Laboratories Ltd., Co.). The
mean interassay CV for the analysis was 3%.
Serum parathyroid hormone concentrations
Serum intact parathyroid hormone (iPTH) was analyzed at
baseline and endpoint at our laboratory with the use of an ELISA
(MDBiosciences, Inc.) on the automatedDynexDS2 ELISA pro-
cessing platform (Dynex Technologies). This 2-site assay is de-
signed to measure biologically iPTH 1–84 and utilizes 2 puri-
fied goat polyclonal antibodies, each specific to a distinct region
on the parathyroid hormone (PTH) molecule. A biotinylated an-
tibody binds to midregion and C-terminal PTH 39–84. The de-
tection antibody, a horseradish peroxidase–conjugated antibody,
binds N-terminal PTH 1–34. The mean intra- and interassay CVs
for this analysis were <3%.
Statistical analysis
Statistical analysis was conducted with the use of SPSS for
Windows version 23.0 (released 2015; IBM Corp., Armonk, NY,
USA). Distribution of the data for all variables at baseline was
tested for normality with the use of histograms and formal tests
(Kolmogorov-Smirnov and Shapiro-Wilk). Data are presented
as means ± SDs, medians (IQRs), and frequencies with percent-
ages, where appropriate. Where data could not be normalized
after transformation, the alternative nonparametric tests were
used. A Mann-Whitney U test assessed the difference in partic-
ipant characteristics between women who completed the trial
and women who had either withdrawn or for whom data were
missing at any stage. Pre- and postintervention 25(OH)D status
and iPTH concentrations within each group were compared by
using paired t tests, as were differences between maternal and
umbilical cord vitamin D metabolites. For continuous data, a
between-group ANOVA with post hoc Tukey’s test was used to
assess the differences in participant characteristics, biochemical
measures, and dietary intakes between the 3 arms of the trial and
a mixed within-between-subject ANOVA assessed changes in
biochemical measures between the groups over time. For com-
parison between categorical variables, including the proportion
of women achieving serum 25(OH)D concentration thresholds
of ≥25, 30, 40, 50, and 75 nmol/L, chi-square tests were used.
Bivariate correlations between variables were examined by
using Pearson or Spearman correlations, where appropriate.
Season of sampling was dichotomized into winter (November–
May) and summer (June–October). Associations between
maternal and umbilical cord vitamin D metabolites, vitamin D
intakes, and iPTH were described by using a linear trendline or
power best-fit curve, where appropriate. P< 0.05 was considered
significant.
Mathematical modeling of distribution of serum 25(OH)D in
relation to total vitamin D intake
Total vitamin D intake was assessed as habitual dietary in-
take plus that derived from personal antenatal supplementation,
if used, plus the intervention dose from the assigned treatment,
on the basis of the analytically verified vitamin D content of the
tablets. The relation between total vitamin D intake and postinter-
vention serum 25(OH)D was described by using the curvilinear
regression model y = b2 + b0 × [1 − exp(–x/b1)], as detailed
previously (16, 17). We conducted an intention-to-treat analysis;
given that the primary outcome was the dose-relation between to-
tal vitaminD intake and achieved 25(OH)D postsupplementation,
all participants who had endpoint data were included, regardless
of compliance. We carried forward data from their own midpoint
assessment for 7 participants who were not available at endpoint,
according to best practice. Ninety-five percent prediction inter-
vals of the required vitamin D intake were calculated to assess
the probable range of intake in the target population. Moreover,
the required vitamin D intakes to maintain 97.5% of the preg-
nant women above serum 25(OH)D thresholds of 25, 30, and 50
nmol/L were estimated from the model by inverse regression ap-
plied to the lower limits of the prediction intervals. In addition,
95% CIs for these vitamin D intakes were obtained with the use
of percentiles from a nonparametric bootstrap procedure based
on 1000 replications. Curvilinear regression models were fitted
to all data and to data stratified by season (summer and winter).
Analyses were carried out by using R version 3.2.2 (23).
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TABLE 2
Baseline characteristics of the 144 participants by treatment group1
Vitamin D3/d
Placebo (n = 48) 10 μg (n = 48) 20 μg (n = 48) P
Age, y 32 ± 4a 34 ± 4a,b 35 ± 3b 0.007
Gestational age, wk 14 ± 2 14 ± 2 14 ± 2 0.87
First-time mother, n (%) 20 (42) 13 (27) 14 (29) 0.26
University education, n (%) 31 (65) 36 (75) 34 (71) 0.53
BMI at 14 wk of gestation, kg/m2 25.7 ± 4.3 26.8 ± 5.1 24.5 ± 3.1 0.095
Season enrolled, n (%)
Winter (November–April) 39 (81) 39 (81) 32 (67) 0.15
Summer (May–October) 9 (19) 9 (19) 16 (33)
Vitamin D intake,2 μg/d 10.6 ± 5.2 10.5 ± 5.4 11.4 ± 5.0 0.43
Calcium intake,2 mg/d 1143 ± 440 1188 ± 571 1216 ± 443 0.76
Vitamin D supplements (yes), n (%) 33 (69) 31 (65) 35 (73) 0.68
Calcium supplements (yes), n (%) 9 (19) 13 (27) 12 (25) 0.61
1Values aremeans± SDs unless otherwise indicated.P values are for differences between groups byANOVA.
Means in the same row without a common superscript letter differ, P < 0.05 (Tukey’s test).
2Includes intake from diet and antenatal supplements.
RESULTS
Recruitment, retention, and adverse events
Our target sample of 144 women completed the baseline visit.
Serum specimens were available for all but 2 women at baseline,
due to the inability to draw blood. A total of 121 women com-
pleted every visit, corresponding to an overall retention rate of
84%. The numbers of women who provided both a baseline and
≥1 follow-up sample (midpoint or endpoint) were 43, 42, and 43
for the placebo and 10- and 20-µg groups, respectively, which
left a final number of 128 for the dose-response analysis. Of the
23 participants who did not provide an endpoint sample, 8 were
due to a pregnancy-associated adverse event, 5 withdrew for per-
sonal reasons, 5 were lost to follow-up, 2 began consuming vi-
tamin D supplements containing >10 µg/d and were excluded,
and 3 delivered their infants before the final visit was conducted.
Overall, 9 adverse events were reported: 1 sexually transmitted
disorder, 1 case of gastrointestinal upset unrelated to the inter-
vention, 1 suspected irritated uterus, 1 miscarriage, 1 chorionic
hematoma, 1 symphysis pubic dysfunction, 1 case of severe hy-
potension, 1 case of pregnancy-induced hypertension, and 1 di-
agnosed case of preeclampsia. The number of adverse events and
withdrawals from the trial did not differ by intervention group
(P > 0.05). There were no differences in the subject characteris-
tics between women with and without a full data set. Compliance
with the intervention was high and was similar between each of
the intervention arms: 79%, 87%, and 90% of participants in the
placebo and 10- and 20-µg/d groups were compliant at the mid-
point visit (P = 0.376) and 67%, 83%, and 76% were compliant
at endpoint (P = 0.310), respectively. A detailed description of
participation retention and progression throughout the study by
treatment group is provided in Figure 1.
Baseline characteristics
Participant characteristics are shown in Table 2. Maternal age
at baseline ranged from 21 to 41 y. Women in the placebo group
were, on average, 3 y younger than women allocated to the
highest vitamin D3-dose group (P = 0.004). Overall, 70% of
participants had a university degree. Thirty-three percent of
women were first-time mothers and 5 women were having a twin
pregnancy (3 in the placebo group and 2 in the 20-μg group).
Total vitamin D and calcium intakes did not differ between the
groups before the intervention (P > 0.05). BMI at first visit was
not associated with baseline 25(OH)D status, nor did BMI in-
fluence the change in maternal 25(OH)D after the intervention
(P > 0.05 for both). More than two-thirds (69%) of women were
taking a vitamin D–containing supplement, from which half ob-
tained 10 µg/d in addition to their dietary intake. Doses ranged
from 0.7 to 10 µg/d and almost all products (97%) contained vi-
tamin D3. Thus, mean total vitamin D intakes, including habit-
ual diet plus supplemental antenatal vitamin D plus the assigned
treatment dose, were 12.1± 8.0, 21.9± 5.3, and 33.7± 5.1 µg/d
in the placebo group and 10- and 20-µg groups, respectively. The
range of total vitamin D intakes was 1.7–53.4 µg/d (68–2136 IU).
Total serum 25(OH)D, iPTH, and albumin-adjusted calcium
concentrations were similar between the treatment groups at
baseline (Table 3). Baseline 25(OH)D was normally distributed,
as confirmed by both Kolmogorov-Smirnov and Shapiro-Wilk
tests. With a mean ± SD concentration of 54.9 ± 22.6 nmol/L,
13% had a 25(OH)D concentration <30 nmol/L and 44%
had concentrations <50 nmol/L. As expected, the prevalence
of women with low vitamin D status was higher in winter
(November–May; 15% <30 nmol/L and 56% <50 nmol/L)
than in summer (June–October; 3% <30 nmol/L and 7% <50
nmol/L). Although only 3% of mothers took a vitamin D2–
containing supplement (dose range: 2.5–10 µg/d), 25(OH)D2 was
detectable (i.e., concentrations more than the LoD) in >98% of
maternal sera, with a sample median concentration of 2.3 nmol/L,
ranging from less than the LoD to 22.0 nmol/L across all time
points.
Effect of vitamin D3 supplementation on maternal serum
total 25(OH)D, iPTH, and calcium
To show the impact of the intervention on maternal serum to-
tal 25(OH)D status, mean 25(OH)D concentrations at each study
visit are shown in Table 3 and the prevalence of women with
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25(OH)D concentrations below a range of thresholds is described
in Table 4. Serum 25(OH)D increased in all groups (Figure 2),
corresponding to mean increases of 5.9 ± 17.3, 33.0 ± 21.7, and
33.4± 23.5 nmol/L from baseline to midpoint in the placebo and
10- and 20-µg groups, respectively (P < 0.05 in all cases), and
of 10.0 ± 24.0, 12.2 ± 16.9, and 7.8 ± 11.0 nmol/L from mid-
point to endpoint in the placebo and 10- and 20-µg groups, re-
spectively (P< 0.05 in all cases). The range of 25(OH)D concen-
trations postintervention was 14.7–150.7 nmol/L. The increase
in 25(OH)D concentrations in the placebo group reflects sea-
sonal variability in vitamin D status, because 81% of women in
this group were recruited in winter and delivered during summer.
Mean maternal serum total 25(OH)D concentrations at 36 wk of
gestation were 24.3 ± 5.8 nmol/L and 29.2 ± 5.6 nmol/L higher
in the 10- and 20-µg groups, respectively, compared with in the
placebo group (P < 0.001) (Table 3).
On completion of the intervention (mean of 36 wk of ges-
tation), no participant in the 10- or 20-µg groups had a serum
25(OH)D concentration <25 nmol/L (Table 4). One woman who
received 10 µg vitamin D had a 25(OH)D <30 nmol/L and 2
had concentrations <50 nmol/L. One participant in the 20-µg
group had a concentration <50 nmol/L. In the placebo group,
8% had a postintervention 25(OH)D concentration <30 nmol/L
and 23% had concentrations <50 nmol/L. Postintervention, 68%
and 84% had concentrations >75 nmol/L in the 10- and 20-µg
groups, respectively. In total, 9% (n = 11) had a 25(OH)D con-
centration >125 nmol/L at endpoint, a threshold designated as
cautionary (pending further data) by the Institute of Medicine in
2011 (1); none were in the placebo group, 5 were taking 10 µg
and 6 were taking 20 µg, with average total intakes of 21.9 and
33.7 µg/d, respectively. There were no significant differences in
serum calcium between treatment groups at any of the time points
(Table 3) and there were no cases of hypercalcemia throughout
the intervention study. There were no significant differences in
serum iPTH between treatment groups at baseline or endpoint
(midpoint not measured) (Table 3), and no significant changes
from baseline to endpoint (P > 0.05). There was a negative cor-
relation between serum 25(OH)D concentrations and iPTH at
both baseline (rho = −0.337, P < 0.001; n = 142) and endpoint
(rho = −0.289, P = 0.006; n = 121).
Dose-response of total vitamin D intake and maternal
25(OH)D
Figure 3 shows the nonlinear relation between total vita-
min D intake and postintervention total 25(OH)D concentrations.
The estimated year-round vitamin D intakes required to main-
tain serum 25(OH)D concentrations ≥25, 30, and 50 nmol/L in
97.5% of gravidae were 11.3, 13.8, and 28.9 µg/d, respectively
(Table 5). Stratification by winter and summer delivered higher
estimates for winter, at 16.2, 18.3, and 30.8 µg vitamin D/d
to meet the ≥25-, 30-, and 50-nmol/L thresholds, respectively,
compared with summer, at 5.8, 8.4, and 23.5 µg/d, respectively
(Table 5).
Umbilical cord 25(OH)D
Mean gestational age at delivery was 39 wk (range: 36–42wk).
In total, 97 umbilical cord blood samples were collected, with
96 matching maternal samples. Maternal and cord blood
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TABLE 4
Prevalence of maternal 25(OH)D concentrations at baseline and endpoint of the intervention study and umbilical cord 25(OH)D concentrations <25, 30, 40,
50, and 75 nmol/L by intervention group1
Treatment group2
Baseline (14 wk mean gestational age) Endpoint (36 wk mean gestational age) Umbilical cord
(n = 142) (n = 121) (n = 97)
25(OH)D Placebo 10 μg/d 20 μg/d P Placebo 10 μg/d 20 μg/d P Placebo 10 μg/d 20 μg/d P
<25 nmol/L 10 10 4 0.48 8a 0b 0b 0.044 19 6 3 0.07
<30 nmol/L 13 17 9 0.51 8 3 0 0.15 31a 15a,b 3b 0.010
<40 nmol/L 27 35 24 0.44 13 5 2 0.16 56a 49a 22b 0.014
<50 nmol/L 40 52 41 0.41 23a 5a,b 2b 0.004 72 67 56 0.41
<75 nmol/L 75 81 74 0.66 45a 32a,b 16b 0.015 97 100 94 0.35
1Values are percentages. P values are for differences in the proportion of women achieving serum 25(OH)D cutoffs between groups by chi-square test.
Means in the same row without a common superscript letter differ, P < 0.05. 25(OH)D, 25-hydroxyvitamin D.
2Represents total vitamin D intakes (including habitual diet plus supplemental vitamin D plus the treatment dose) of 12.1± 8.0, 21.9± 5.3, and 33.7± 5.1
µg/d in the placebo and 10- and 20-µg groups, respectively.
25(OH)D concentrations were highly correlated (r = 0.789,
P < 0.001; n = 96, Figure 4A), with mean cord 25(OH)D
concentrations reflecting an average of 52% of maternal values
(range: 28–79%). Infants born to mothers in the placebo group
had significantly lower 25(OH)D concentrations than those born
to mothers in the 20-µg group (mean ± SEM difference: 11.3
± 3.83 nmol/L; P = 0.011), with no significant difference in
mean cord values between group receiving 10 µg and the other 2
treatment arms (Table 3). Thirty-one percent of newborns born
to mothers in the placebo group had 25(OH)D concentrations
<30 nmol/L compared with 3% of those receiving 20 µg
(P = 0.008) (Table 4). Cord 25(OH)D concentrations did not fall
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FIGURE 2 Mean maternal serum 25(OH)D concentrations achieved at
each time point by intervention group. n = 40, 35, and 43 for the placebo and
10- and 20-µg groups, respectively, in which the analysis includes women
who provided a blood sample at all 3 time points. Total mean ± SD vitamin
D intakes (including habitual diet and supplementation plus treatment dose)
were 12.1 ± 8.0, 21.9 ± 5.3, and 33.7 ± 5.1 µg/d in the placebo and 10-
and 20-µg groups, respectively. Mean gestational age = 14, 24, and 36 wk
at baseline, midpoint, and endpoint, respectively. Differences in mean serum
25(OH)D within groups from baseline to endpoint were all significantly dif-
ferent (P < 0.01 in all cases, paired-samples t test for each group). 25(OH)D,
25-hydroxyvitamin D.
below 25 and 30 nmol/L when maternal 25(OH)D concentrations
at 36 wk of gestation were ≥44 and 55.4 nmol/L, respectively
(Figure 4A). When maternal 25(OH)D concentration was ≥50
nmol/L, cord concentrations were ≥25 nmol/L in all but 1 and
≥30 nmol/L in 95% of newborns.
Other serum vitamin D metabolites
The effects of the vitamin D3 intervention on maternal and
cord serum 3-epi-25(OH)D3 and 24,25(OH)2D3 concentrations
at each study visit are shown in Table 3. Serum 3-epi-25(OH)D3
was detectable in all maternal samples, with the exception
of 2 mothers at baseline who had a 25(OH)D3 concentration
<12 nmol/L. 3-Epi-25(OH)D3 increased in line with treatment
dose and showed a dose-dependent difference (P< 0.001) at mid-
point, with no difference between the 10- and 20-µg groups at
endpoint. The median (IQR) molar ratio of 25(OH)D3 to 3-epi-
25(OH)D3 was 30.0 (12.8), 25.4 (9.6), and 21.2 (25.0) at baseline,
midpoint, and endpoint, respectively, indicating an increase in the
relative expression of 3-epi-25(OH)D3 as pregnancy progressed
(P< 0.001), which did not differ by intervention dose (P= 0.93).
3-Epi-25(OH)D3 was detectable in 100%of cord sera; themedian
(IQR) molar ratio of 25(OH)D3 to 3-epi-25(OH)D3 was lower
than in pregnancy at 10.8 (3.1) (P < 0.001), and the correlation
betweenmaternal and cord 3-epi-25(OH)D3 was 0.8 (P< 0.001).
Maternal 24,25(OH)2D3 concentrations increased with in-
creasing 25(OH)D3, as shown in Figure 5A. As 25(OH)D3 in-
creased, the ratio of 25(OH)D3 to 24,25(OH)2D3 decreased. At
36 wk of gestation, the association between the maternal ratio
of 25(OH)D3 to 24,25(OH)2D3 and 25(OH)D3 was r = −0.479
(P < 0.001), indicating ratios of ∼20 and ∼18 at serum
25(OH)D3 concentrations of 30 and 50 nmol/L, respectively
(Figure 5B). Similarly, associations of cord 24,25(OH)2D3 and
25(OH)D3 and the cord ratio of 25(OH)D3 to 24,25(OH)2D3 and
25(OH)D3 are shown in Figure 6. There was a strong correlation
between maternal and cord ratios of 25(OH)D3 to 24,25(OH)2D3
(r = 0.553, P < 0.001; n = 95), with a lower mean ± SD molar
ratio of 25(OH)D3 to 24,25(OH)2D3 in cord (12.9 ± 3.8) than in
maternal (15.1 ± 5.4) sera sampled in late gestation (P < 0.001)
(Figure 4B, C). Finally, associations between 24,25(OH)2D3 and
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FIGURE 3 The relation between achieved serum 25(OH)D concentrations and total vitamin D intake in pregnant women living at 51.9°N, assessed by
using a curvilinear regression model. The mean response is indicated by the central line, and the outer lines are its 95% prediction intervals; n= 128. Horizontal
lines represent serum 25(OH)D thresholds of 25, 30, and 50 nmol/L, respectively. 25(OH)D, 25-hydroxyvitamin D.
the ratio of 25(OH)D3 to 24,25(OH)2D3 and vitamin D intake are
shown in Figure 7.
DISCUSSION
Despite growing evidence to support a role for vitamin D in
perinatal and infant health, pregnancy-specific 25(OH)D targets
are not available thus far, which presents a risk to maternal and
fetal health. On the basis of current knowledge, reflected in the
TABLE 5
Estimated vitamin D intakes to maintain serum 25(OH)D above selected
thresholds in 97.5% of pregnant women at 51.9oN, year-round, during
winter and summer1
Vitamin D intakes, µg/d
25(OH)D Year-round Winter Summer
>25 nmol/L 11.3 (6.8, 15.0) 16.2 (9.9, 21.9) 5.8 (1.1, 10.6)
>30 nmol/L 13.8 (8.8, 18.1) 18.3 (11.7, 24.3) 8.4 (2.0, 13.1)
>50 nmol/L 28.9 (20.6, 41.1) 30.8 (19.5, 40.7) 23.5 (14.0, 30.6)
1Values are the vitamin D intakes (95% CIs) that will maintain serum
25(OH)D >25, 30 and 50 nmol/L in 97.5% of white-skinned pregnant
women. Results are based on a nonlinear regressionmodel of serum 25(OH)D
concentration as a function of vitamin D intake (y = b2 + b0 × [1 − exp(–
x/b1)]), n = 128; 95% CIs for the lower prediction limits were obtained with
the use of bias-corrected bootstrap procedures based on 1000 replications.
Winter season of delivery was defined as November–May; summer season of
delivery was defined as June–October. 25(OH)D, 25-hydroxyvitamin D.
reports from international agencies (1–4) and consensus groups
(8, 21), the prevention of newborn vitamin D deficiency, in the
context of protecting the fetal and newborn skeleton, is an appro-
priate foundation for specifying meaningful maternal 25(OH)D
targets and the vitamin D intakes to meet them. In this dose-
response, double-blind, placebo-controlled RCT conducted from
14 wk of gestation to late pregnancy, we estimated that a ma-
ternal vitamin D intake of ∼30 µg/d (1200 IU) would maintain
25(OH)D concentrations ≥50 nmol/L in 97.5% of women in late
pregnancy, which would prevent 95–99% of umbilical cord sera
falling below the minimum 25(OH)D thresholds associated with
the prevention of adverse consequences for bone health in new-
borns, at 25–30 nmol/L.
Until now, the question of protecting newborn infants from
very low vitamin D status has not been specifically addressed and
maternal vitamin D requirements have been considered in isola-
tion from the fetal and neonatal requirement. Our study shows
that the 25(OH)D thresholds of 25 and 30 nmol/L proposed by
the United Kingdom (3) and the Institute of Medicine (1) as in-
dicative of an increased risk of vitamin D deficiency, on the basis
of bone health outcomes, would be achieved by 97.5% of moth-
ers with a total vitamin D intake of 11 and 14 µg/d, respectively.
Because our recruitment strategy covered the calendar year, strat-
ification of the dose-response analysis by winter and summer
season of delivery was possible. There was a wide variation in
season-specific intake estimates at the lower 25(OH)D thresh-
olds, from 18 to 8 μg/d to meet the 30-nmol/L threshold and
from 16 to 6 μg/d to meet the 25-nmol/L threshold, in winter and
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FIGURE 4 Association of maternal 25(OH)D at 36 wk of gestation and umbilical cord 25(OH)D concentrations (linear trendline: y = 0.4391x + 5.6922;
R² = 0.62; n = 96; r = 0.79, P < 0.001) (A). The vertical line represents maternal 25(OH)D at 50 nmol/L, and the horizontal lines represent cord 25(OH)D
at 25 and 30 nmol/L. When maternal 25(OH)D concentration was ≥50 nmol/L, cord concentrations were ≥25 nmol/L in all but 1 and ≥30 nmol/L in 95% of
newborns. Association of maternal 24,25(OH)2D3 at 36 wk of gestation and umbilical cord 24,25(OH)2D3 (power fit trendline: y = 0.9715x0.6905; R² = 0.68;
n = 95; r = 0.80, P < 0.001) (B). Association of the ratio of maternal 25(OH)D3 to 24,25(OH)2D3 at 36 wk of gestation and the ratio of umbilical cord
25(OH)D3 to 24,25(OH)2D3 (power fit trendline: y= 2.9938x0.5346; R²= 0.33; n= 95; r= 0.55, P < 0.001) (C). 25(OH)D, 25-hydroxyvitamin D; 25(OH)D3,
25-hydroxyvitamin D3; 24,25(OH)2D3, 24,25-dihydroxyvitamin D3.
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FIGURE 5 Association of maternal 25(OH)D3 and 24,25(OH)2D3 concentrations at 36 wk of gestation (power fit trendline: y = 0.0162x1.3309; R²= 0.80;
n= 121; r= 0.86, P< 0.001) (A); association of maternal 25(OH)D3 concentrations and the ratio of 25(OH)D3 to 24,25(OH)2D3 at 36 wk of gestation (power
fit trendline: y = 61.575x−0.331; R² = 0.20; n = 121; r = –0.48, P < 0.001) (B). 25(OH)D3, 25-hydroxyvitamin D3; 24,25(OH)2D3, 24,25-dihydroxyvitamin
D3.
summer, respectively. This variability highlights not only the sea-
sonal changes in the contribution of UV-B availability to vitamin
D status at a northern latitude (24) but also the vulnerability of
womenwith little UV-B exposure and low vitaminD intakes to vi-
taminD deficiency duringwinter. Because gestation occurs over a
40-wk period, vitamin D recommendations for pregnancy based
on year-round estimates are likely to be most appropriate.
The current intakes required to meet particular 25(OH)D tar-
gets in pregnancy extend the findings of our recent individual par-
ticipant data–level meta-analysis involving 882 healthy children
and adults from 7 winter-based RCTs, in which we reported that
intakes of 10, 13, and 26 µg vitamin D/d would maintain winter
serum 25(OH)D concentrations of >25, 30, and 50 nmol/L, re-
spectively (25). At each 25(OH)D threshold, current vitamin D
estimates for pregnant women are similar, albeit slightly higher
than the individual participant data analysis.
The current data, which show protection of newborn vitamin
D status at minimum thresholds of 25–30 nmol/L with mater-
nal 25(OH)D concentrations ≥50 nmol/L, confirm suggestions
from 2 trials in Canada (13) and New Zealand (12), which con-
curred that although 10 µg vitamin D/d may prevent mater-
nal 25(OH)D falling below 30 nmol/L, a minimum of 25 µg/d
might be needed to maintain newborn 25(OH)D at similar con-
centrations. The UK-based Maternal Vitamin D Osteoporosis
Study (MAVIDOS) showed that supplementation with 25 µg/d
was sufficient to prevent the seasonal decline in 25(OH)D sta-
tus among women delivering in winter and maintained 83% at
concentrations ≥50 nmol/L (26). Both Hollis et al. (27) and Da-
wodu et al. (28) reported higher dosing regimens of ≤100 µg/d
in 2 distinct population groups in the United States and United
Arab Emirates, respectively, noting large disparities in the range
of 25(OH)D obtained, whereas the loading dose of 1750 µg
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FIGURE 6 Association of umbilical cord 25(OH)D3 and 24,25(OH)2D3 concentrations (power fit trendline: y= 0.0794x1.0036; R²= 0.71; n= 95; r= 0.82,
P < 0.001) (A); association of the ratio of umbilical cord 25(OH)D3 concentrations and the ratio of 25(OH)D3 to 24,25(OH)2D3 (linear trendline: y =
–0.0353x + 14.473; R² = 0.02; n = 95; r = –0.14, P = 0.173) (B). 25(OH)D3, 25-hydroxycholecalciferol; 24,25(OH)2D3, 24,25-dihydroxycholecalciferol.
followed by 875 µg/wk (125 µg/d) used by Roth et al. (29) en-
sured that all women in the Bangladesh trial reached 50 nmol/L.
It is important to acknowledge that the wide range of 25(OH)D
concentrations achieved in intervention trials to date results from
variations in study design, latitude, vitamin D status, and nu-
tritional status of the sample populations before intervention. A
selection of vitamin D intervention studies in pregnancy is sum-
marized in Supplemental Table 1 to enable a thorough compar-
ison of doses and 25(OH)D concentrations achieved.
Calcium intakes are not presented in most studies of vitamin
D in pregnancy, which adds to the variability between trial data.
Disruptions in calcium homeostasis during pregnancy arise from
inadequate dietary calcium or secondary hyperparathyroidism re-
sulting from low vitamin D status. In the current study, serum
iPTH was unchanged from the beginning to the end of the in-
tervention period, irrespective of the treatment dose. Dietary
recommendations for vitamin D are established with the assump-
tion that dietary calcium intakes are adequate (1–4). In our sam-
ple, 22% had calcium intakes below the current US Estimated
Average Requirement of 800 mg (1). Adolescents and ethnic mi-
norities, who may have a higher prevalence of low calcium in-
takes, should be considered separately, because this may affect
the vitamin D–25(OH)D dose-response relation in these groups.
Due to a lack of certainty surrounding the threshold at which
the risk of hypercalcemia increases and some evidence for a re-
verse J-shaped relation between high 25(OH)D concentrations
and adverse outcomes, caution has been urged with regard to vita-
min D dosing, particularly in pregnancy (1). In the current study,
no participant exceeded the Tolerable Upper Intake Level of
100μg/d (1, 4), whichwas set on the basis of avoiding the adverse
effect of hypercalcemia. Although a small proportion of women
(9%; n = 11) achieved a serum 25(OH)D concentration above
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FIGURE 7 Association of maternal vitamin D intake and 24,25(OH)2D3 concentrations (power fit trendline: y = 1.604x0.4247; R² = 0.20; n = 121;
r = 0.401, P < 0.001) (A); association of maternal vitamin D intake and the ratio of 25(OH)D3 to 24,25(OH)2D3 at 36 wk of gestation (power fit trendline:
y = 21.431x−0.135; R² = 0.08; n = 121; r = −0.26, P = 0.004) (B). 25(OH)D3, 25-hydroxycholecalciferol; 24,25(OH)2D3, 24,25-dihydroxycholecalciferol.
the cautionary threshold of 125 nmol/L (1), with total intakes of
21–34 μg/d (1), we did not detect any hypercalcemia. Doses of
≤100 µg/d have been shown to be safe in pregnancy, with no
indication of hypercalcemia or hypercalciuria even at 25(OH)D
concentrations >240 nmol/L (27, 30). Our dosing strategy plus
careful assessment of background vitamin D intakes were con-
servative and are a strength of the study, because this minimized
risk while achieving the target 25(OH)D concentrations, albeit in
a highly compliant sample.
In agreement with our recent report (9), we confirmed
that 3-epi-25(OH)D3 was present in almost all maternal and
all infant cord sera, and, to our knowledge, these are the
first data showing an increase in the relative expression of
3-epi-25(OH)D3 as pregnancy progresses, independent of sup-
plemental vitamin D intake.We have also presented the first dose-
response data of 24,25(OH)2D3 in a pregnancy trial and observed
strong correlations between maternal 24,25(OH)2D3 and
25(OH)D3 and between maternal 24,25(OH)2D3 and total
vitamin D intake. Compared with nonpregnant adults (31), the
ratio of 25(OH)D3 to 24,25(OH)2D3 in pregnant women was
slightly higher. At 25(OH)D concentrations of 30 and 50 nmol/L,
the ratios of 25(OH)D3 to 24,25(OH)2D3 were ∼20 and 18 in
pregnant women compared with ∼18 and 15 in nonpregnant
adults, suggesting lower 24-hydroxylase [CYP24A1] activity in
late pregnancy. Hanson et al. (32), in an observational study in
131 maternal-cord dyads, reported identical ratios of 25(OH)D3
to 24,25(OH)2D3 in mothers and cords, at 18.5, alongside
highly correlated maternal and cord metabolite concentrations
(r = 0.78, 0.90, and 0.89 for 25(OH)D3, 24,25(OH)2D3, and
3-epi-25(OH)D3, respectively). With similar cord and higher
average postintervention maternal 25(OH)D concentrations,
our metabolite correlations were in the same range (r = 0.8),
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and there was a strong correlation between maternal and cord
ratios of 25(OH)D3 to 24,25(OH)2D3, but we observed a lower
molar ratio of 25(OH)D3 to 24,25(OH)2D3 in cord blood, at
13, compared with maternal sera, at 15. This may be partly
attributable to the wider distribution of our intervention data
compared with the observational study.
This trial has a number of strengths, including CDC-accredited
analysis of 25(OH)D and metabolites and the use of a method
traceable to the NIST higher-order reference measurement pro-
cedure. Our vitamin D intake assessment was validated for the
measurement of habitual vitamin D intake in females of different
ages and has been implemented in almost 1000 trial participants
to date (19). Both compliance with the intervention and over-
all retention rate were high, and we detected no hypercalcemia
or intervention-related adverse events. Because our sample was
confined to white women, our findings are not generalizable to
all women, and we recommend that the protocol be repeated in
ethnicity-specific studies, because the food-frequency question-
naire would need to be tailored and the dose-response relation
may vary.
In conclusion, we report evidence for an increased dietary re-
quirement for vitamin D among white pregnant women than is
currently recommended. We have shown that a total vitamin D
intake of 30 µg/d is sufficient to maintain serum 25(OH)D con-
centrations≥50 nmol/L in 97.5% of gravidae at high latitude and
will prevent 95–99% of umbilical cord 25(OH)D concentrations
falling to<25–30 nmol/L, a clinically relevant and achievable tar-
get. The question of whether pregnancy-specific thresholds based
on perinatal outcomes are required is still outstanding.
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